If you have been reading about pentadecapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
=== ESI variations === There are some ESI methods that require little to no sample preparation. One such method is a method termed extractive electrospray ionization (EESI). This method involves having an electrospray of solvent directed at an angle against a different spray of the sample solution, produced by a separate nebulizer. This method requires no sample preparation in that the electrospray of solvent extracts the sample from the complex mixture, effectively removing any background contaminants. Another particularly powerful variation on ESI is desorption electrospray ionization (DESI), which involves directing an electrospray at a surface with the sample deposited on top of it. The sample is ionized in the electrospray as it splashes off the surface, then traveling to the mass spectrometer. This method is important because no sample preparation is needed for this method. A sample simply needs to be deposited on a surface, such as paper. Atmospheric pressure chemical ionization (APCI) is similar to ESI in that the sample is nebulized in droplets that are then evaporated, leaving behind a charged ion to be analyzed. APCI experiences few of the negative matrix effects experienced by ESI due to the fact that ionization occurs in the gas phase in this method rather than the within the liquid droplets as in ESI and the fact that in APCI there is an overabundance of reaction gas, thus minimizing the effect of the matrix on the ionization process.
Such glare can lead to serious accidents and, in the case of pilots and truck drivers, to occupational disability due to eye damage. The first accident prevention regulation was published on April 1, 1988 as BGV B2, followed on January 1, 1997 by DGUV Regulation 11 of the German Social Accident Insurance. Between January and mid-September 2010, the German Federal Aviation Office registered 229 dazzle attacks on helicopters and airplanes of German airlines nationwide. On October 18, 2017, a perpetrator of a dazzle attack on a federal police helicopter was sentenced to one year and six months in prison without parole.
=== Function === ACTH released from the corticotropes binds to G protein-coupled receptors in the adrenal cortex, where it stimulates the production of glucocorticoids (primarily cortisol). ACTH binds to the melanocortin 2 receptor and, through signal transduction, increases levels of cholesterol esterase, the transport of cholesterol across the mitochondrial membrane, cholesterol binding to P450SCC and, an increase in pregnenolone synthesis. It also serves as a secondary stimulus for the synthesis of mineralocorticoids such as aldosterone, which serve an important role in regulating the salt balance of the blood. Glucocorticoids released by the adrenal cortex inhibit production of CRH and ACTH, forming a negative feedback loop.
== Other applications == Decontamination: Prolidase from the hyperthermophilic archaeon Pyrococcus furiosus (Pfprol) shows potential for application in decontamination of organophosphorus nerve agents in chemical warfare agents. Additionally, prolidase could also serve to detect fluorine-containing organophosphorus neurotoxins, like the G-type chemical warfare agents, and could antagonize organophosphorous intoxication and protect against the effects of diisopropylfluorophosphate when encapsulated in liposomes.
According to his father, the loan spells were the making of his son's career, while Tottenham's former Director of Football Damien Comolli, who was dismissed in October 2008, believes Townsend succeeded in spite of the way Tottenham handled him.
Sources: en.wikipedia.org
== Chemistry == In the kidneys, the enzyme AGAT catalyzes the conversion of two amino acids—arginine and glycine—into guanidinoacetate (also called glycocyamine or GAA), which is then transported in the blood to the liver. A methyl group is added to GAA from the amino acid methionine by the enzyme GAMT, forming non-phosphorylated creatine. This is then released into the blood by the liver where it travels mainly to the muscle cells (95% of the body's creatine is in muscles), and to a lesser extent the brain, heart, and pancreas. Once inside the cells it is transformed into phosphocreatine by the enzyme complex creatine kinase. Phosphocreatine is able to donate its phosphate group to convert adenosine diphosphate (ADP) into adenosine triphosphate (ATP). This process is an important component of all vertebrates' bioenergetic systems. For instance, while the human body only produces 250 g of ATP daily, it recycles its entire body weight in ATP each day through creatine phosphate. Phosphocreatine can be broken down into creatinine, which is then excreted in the urine. A 70 kg man contains around 120 g of creatine, with 40% being the unphosphorylated form and 60% as creatine phosphate. Of that amount, 1–2% is broken down and excreted each day as creatinine. Phosphocreatine is used intravenously in hospitals in some parts of the world for cardiovascular problems under the name Neoton, and also used by some professional athletes, as it is not a controlled substance.
The ineffectual response was caused by feuding officials who refused to co-operate with each other contributed to the death toll. It took weeks for aid to reach some villages, causing much resentment in Calabria. To offset widespread criticism that the government in Rome did not care about Calabria, King Victor Emmanuel III personally took over the relief operation and toured the destroyed villages of Calabria, which won the government a measure of popularity. Notably, after the king took charge, the feuding ceased and aid started to flow.
GoodRx Holdings, Inc. is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications. GoodRx compares prescription drug prices at more than 75,000 pharmacies in the United States. The platform allows users to consult a doctor online and obtain a prescription for certain types of medications.
=== Discovery and synthesis === The hormonal action of progesterone was discovered in 1929. Pure crystalline progesterone was isolated in 1934 and its chemical structure was determined. Later that year, chemical synthesis of progesterone was accomplished. Shortly following its chemical synthesis, progesterone began being tested clinically in women.
Sources: en.wikipedia.org
== Further reading == Glutathione synthetase deficiency at NLM Genetics Home Reference Beutler, E; Gelbart, T; Pegelow, C (1986). "Erythrocyte glutathione synthetase deficiency leads not only to glutathione but also to glutathione-S-transferase deficiency". Journal of Clinical Investigation. 77 (1): 38–41. doi:10.1172/JCI112298. PMC 423305. PMID 3944259.
In the drug discovery process of a 5-HT2C agonist, a pharmacophore module has been used to discover novel 5-HT2C receptor ligands. The pharmacophore has four features; one aromatic ring, two hydrophobic features and one positive ionizable feature. Figure 4 shows an example of a compound that fits the agonist pharmacophore perfectly. The nitrogen atom of piperazine fits the positive ionizable feature, the benzofuran part fits the aromatic ring and one hydrophobic, and the trifluoromethane part fits another hydrophobic feature of the pharmacophore.
=== First attempts, halting follow-up === When jamming was first attempted by the Germans it was in a much more clever fashion than had been anticipated. The observation that the transmissions of the individual stations were spread out in time, in order to avoid mutual interference, was exploited. A system was designed to send back spurious broadband pulses on a chosen CH station's time slot. The CH operator could avoid this signal simply by changing their time slot slightly, so the jamming was not received. This caused the station's signals to start overlapping another's time slot, so that station would attempt the same cure, affecting another station in the network, and so forth. A series of such jammers were set up in France starting in July 1940, and soon concentrated into a single station in Calais that affected CH for some time. However, the timing of these attempts was extremely ill-considered. The British quickly developed operational methods to counteract this jamming, and these had effectively eliminated the effect of the jamming by the opening of the Battle of Britain on 10 July. The Germans were well on their way to develop more sophisticated jamming systems, but these were not ready for operation until September. This meant that the CH system was able to operate unmolested throughout the Battle, and led to its well-publicized successes. By the opening of the Battle in July the German Luftwaffe operational units were well aware of CH, and had been informed by the DVL that they could not expect to remain undetected, even in clouds.
=== Scottish === Daughters of Scotland - Incorporated in Ohio on October 3, 1899. Membership is open only to those of Scottish blood. Rituals had signs, oaths, and prayers. Grand Lodge dissolved in the early 1970s, though some local groups continued to meet afterwards. Order of Scottish Clans Sons of Scotland Benevolent Association - Founded 1876 in Toronto. Incorporated in Ontario in 1880, and on the federal level in 1937. Headquartered in Toronto, the association's lodges are called "Subordinate Camps", and the national structure is "Grand Camp", which meets in conventions triennially. Slogan "Lealty, Loyalty, Liberality". In the late 1970s, it still had an initiation ceremony and "affinity for fraternal ritualism", annual passwords, and regalia. In addition to insurance, it sponsors Scottish dancing and piping competitions, and parades in Scottish kilts. Membership is open to men and women of Scottish descent or their spouses. Five classes of membership - insured, central camp, juvenile, associate, and at large. Members are chosen by blackball. 1973 membership 12,887; 1979 membership 12,640 in 80 camps. 9,000 members in 1995. Charitable activities include Kidney Foundation of Canada and Alzheimer's disease organizations. Lost a third of its membership over the 1980s.
Females are more aggressive than males during the courtship period, often fighting for access to mates, with fights among females accounting for more than half the aggressive interactions during this period. If females court a male that already has a partner, the incumbent female will try to repel the competitor, usually by chasing and kicking. These interactions can be prolonged, lasting up to five hours, especially when the male being fought over is single and neither female has the advantage of incumbency. In these cases, the females typically intensify their calls and displays. The sperm from a mating is stored by the female and can suffice to fertilise about six eggs. The pair mate every day or two, and every second or third day the female lays one of a clutch of five to fifteen very large, thick-shelled, green eggs. The shell is around 1 mm (0.04 in) thick, but rather thinner in northern regions according to indigenous Australians. The shell is substantially composed of calcite, and its δ13C is a function of the emu's diet. The eggs are on average 13 cm × 9 cm (5.1 in × 3.5 in) and weigh between 450 and 650 g (1.0 and 1.4 lb). The maternal investment in the egg is considerable, and the proportion of yolk to albumen, at about 50%, is greater than would be predicted for a precocial egg of this size. This probably relates to the long incubation period which means the developing chick must consume greater resources before hatching. The first verified occurrence of genetically identical avian twins was demonstrated in the emu. The egg surface is granulated and pale green.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.